The Town Ozempic Built: What It Means for You

A Small Town That Changed Weight Loss Medicine Forever

If you've ever wondered why Ozempic feels like it's everywhere, part of the answer lies in a small town in Denmark called Kalundborg.

This is where Novo Nordisk, the pharmaceutical company behind semaglutide, manufactures a significant portion of its GLP-1 supply. The town's economy, infrastructure, and identity have been so thoroughly shaped by the drug's success that journalists and analysts have taken to calling it "the town Ozempic built." Factories have expanded. New workers have arrived. Local services have grown to support the surge.

But what does a Danish manufacturing hub have to do with your ability to get a GLP-1 prescription filled at your local pharmacy in Ohio or Texas? More than you might expect.

Why the Manufacturing Story Matters to Patients

When demand for a drug outpaces the ability to produce it, patients feel the consequences directly.

Semaglutide became one of the fastest-growing drugs in pharmaceutical history. Wegovy, the higher-dose version approved for chronic weight management, launched to overwhelming demand in 2021. Ozempic, its sister formulation approved for type 2 diabetes, was being prescribed off-label for weight loss at the same time. The combined pressure on Novo Nordisk's supply chain was enormous.

The result was a prolonged shortage that left many patients unable to refill their prescriptions and forced others to switch doses, delay treatment, or pay out-of-pocket for compounded alternatives. Even with Kalundborg expanding capacity, supply has struggled to keep pace with global demand.

Understanding this context helps you anticipate what might happen next, and how to protect your access to treatment.

The Shortage That Shaped the GLP-1 Market

The FDA placed semaglutide on its drug shortage list, which had a cascading effect on the entire GLP-1 market.

When a drug is officially listed as scarce, compounding pharmacies are legally permitted to produce copies of it. This opened the door to a wave of compounded semaglutide products, typically sold at a fraction of the brand-name price. For many patients who couldn't afford or access Ozempic or Wegovy, these compounded versions became a lifeline.

The FDA removed semaglutide from the shortage list in early 2025, signaling that Novo Nordisk had largely caught up with demand. That decision triggered a new wave of uncertainty: compounding pharmacies were given a wind-down period but eventually faced restrictions on continuing to produce semaglutide. For patients who had built their routines around compounded versions, this created a real access problem.

If you're currently using a compounded GLP-1, it's worth discussing your options with your provider now rather than waiting for a disruption.

How Novo Nordisk's Growth Affects Drug Pricing

Novo Nordisk's meteoric rise, fueled almost entirely by GLP-1 drugs, briefly made it the most valuable company in Europe. That kind of financial power comes with pricing implications that affect every patient.

List Price vs. What You Actually Pay

The list price for Wegovy in the United States sits above $1,300 per month. Ozempic's list price is similar. However, most insured patients with coverage pay significantly less, and manufacturer savings programs can reduce costs further for eligible individuals.

The gap between what the drug costs to produce and what it costs at the pharmacy reflects not just manufacturing expenses, but years of research investment, patent protection, and the enormous marketing apparatus that made semaglutide a household name. You're paying for all of that.

Here's a simplified breakdown of typical patient costs across different access scenarios:

Checking the GLP-1 Coupons page before you fill a prescription can make a meaningful difference in what you actually pay.

The Tirzepatide Variable: Competition Changes Everything

Novo Nordisk no longer operates in a vacuum. Eli Lilly's Mounjaro (tirzepatide) arrived with clinical data showing weight loss results that, in some trials, outperformed semaglutide. Zepbound, tirzepatide's weight-loss-specific formulation, added another option for patients.

Competition matters for pricing and access. When two major pharmaceutical companies are racing to capture the GLP-1 market, both have stronger incentives to keep their products accessible, offer savings programs, and work with insurers on coverage. That's good news for patients, even if the benefits aren't always immediate or evenly distributed.

Tirzepatide also faced its own shortage period, so the supply chain challenges are not unique to semaglutide. What the emergence of multiple GLP-1 options does provide is a fallback if one drug becomes unavailable or unaffordable for you.

Talk with your provider about whether switching between semaglutide and tirzepatide is clinically appropriate for your situation. Some patients do better on one than the other, and individual response varies.

What This Means for Patients Choosing a Provider

The story of Ozempic's rise is also a story about the healthcare infrastructure that grew around it. Telehealth platforms, weight loss clinics, and online prescribers expanded rapidly to meet patient demand, especially when traditional primary care offices were slow to engage with GLP-1 prescribing.

Questions to Ask Before You Commit to a Provider

Choosing the right provider affects not just your prescription, but your experience managing costs, side effects, and dose adjustments over time. Before signing up with any service, consider asking:

• Does this platform require a real clinical evaluation before prescribing, including a review of my medical history, current medications, and any contraindications, or is it primarily a form-based process with minimal provider oversight?
• What happens after my first prescription is issued? Does the platform offer structured follow-up appointments, dose adjustment support, and check-ins, or is the model primarily prescription-and-refill with limited clinical engagement?
• Which pharmacy does this provider work with, and how reliably have they been able to fill GLP-1 prescriptions during shortage periods or supply fluctuations?
• If my insurance denies coverage, does this provider offer assistance with prior authorization appeals or letters of medical necessity, or is that left entirely to me?
• What is the total monthly cost including the consultation fee, medication cost, and any platform subscription, and how does that compare to going through my primary care doctor and a retail pharmacy?
• If I experience side effects or need a dose adjustment, how quickly can I reach a provider, and through what channel, such as messaging, video call, or phone?
• Does this platform prescribe both semaglutide and tirzepatide, so I have the option to switch if one medication is unavailable or not producing adequate results for my situation?

The Best Providers comparison page on GLP-1.com can help you evaluate current options side by side, including cost structures and what's included in each program.

The Global Ripple Effect You Don't See at the Pharmacy

One aspect of the "town Ozempic built" story that gets less attention is what Novo Nordisk's dominance means outside the United States.

In Denmark, the company's profits have become a significant portion of the national economy. The factory expansions in Kalundborg represent billions in investment. But in lower-income countries, that same pricing power means semaglutide is largely out of reach for patients who could benefit from it.

Globally, the GLP-1 story raises real questions about drug pricing equity that are still being debated. The World Health Organization and various health economists have pointed to GLP-1 drugs as a test case for how innovation gets distributed across different healthcare systems.

For patients in the United States, this context is a reminder that the cost you pay isn't inevitable. It reflects policy choices, patent law, and negotiating leverage. Staying informed about legislative changes, such as potential Medicare negotiation of GLP-1 prices, can affect your long-term costs significantly.

Supply Chain Lessons: How to Protect Your Access

If the semaglutide shortage taught patients anything, it's that consistent access to GLP-1 medication requires some proactive planning. Stopping and restarting GLP-1 therapy isn't ideal clinically, and the regain that can follow a treatment interruption is a documented pattern in the research.

Practical Steps to Reduce Disruption Risk

• Fill your prescription as early as your plan allows rather than waiting until your last dose. Most insurance plans and pharmacy benefit managers permit refills when you have a week or two of medication remaining, and building even a small buffer protects you during supply disruptions.
• Ask your provider whether a 90-day supply is available and covered under your plan. Longer fills reduce the frequency of potential access interruptions and often come with lower per-dose costs at retail pharmacies.
• Keep your prescriber informed of any supply issues you encounter at your pharmacy, since they may be able to redirect your prescription to a different pharmacy with better stock, authorize a dose substitution, or document a temporary plan if a gap occurs.
• Know your fallback options before you need them. If your brand-name GLP-1 becomes unavailable, understand in advance whether your provider is comfortable prescribing the alternative formulation, such as tirzepatide if you are on semaglutide, and whether your insurance would cover it.
• Monitor FDA shortage list updates periodically, since the status of semaglutide and tirzepatide on that list directly affects what compounding pharmacies can legally produce and sell, which in turn affects your backup options.
• If you are currently using a compounded GLP-1 product, have a conversation with your provider now about transitioning to an FDA-approved branded version before a regulatory deadline forces an unplanned switch, since an abrupt transition can disrupt your dosing schedule and titration progress.
• Document your treatment history, including your starting weight, current dose, duration of therapy, and any weight-related health conditions, so that if you need to switch providers or pharmacies quickly, you can provide a clear clinical picture without delays.